Share

ENBREL Phase III Data Published In Annals Of Internal Medicine

Pivitol Study of ENBREL in Rheumatoid Arthritis Patients Established Foundation for FDA Approval

Who: Immunex Corporation (NSQD:IMNX) and Wyeth-Ayerst Laboratories, a division of American Home Products Corporation (NYSE:AHP), announce the publication of Phase III data for ENBREL (etanercept) for the treatment of rheumatoid arthritis (RA) in the Annals of Internal Medicine.

What: The six month study is based on 234 patients with active rheumatoid arthritis with inadequate response to DMARDs.

Date of Publication: March 16, 1999

Spokespeople: Study investigators, company spokespersons and patients on ENBREL are available for interviews

Contact:
Shari Beagelman 212-614-4673; Shari_beagelman@bm.com
Nicole Preiss 212-614-5237; Nicole_preiss@bm.com

Background: ENBREL was approved November 2, 1998 by the U.S. Food and Drug Administration as a treatment for moderately to severely active RA in patients who have an inadequate response to one or more disease modifying anti-rheumatic drugs (DMARDs).

Share

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.